Clair Harris

TL;DR: Although HARP-2 found no difference in 28-day survival between placebo and simvastatin, significantly different survival was identified across patients stratified by treatment and subphenotype (p<0·0001), and within the hyperinflammatory subphenotypes, patients treated with simVastatin had significantly higher 28- day survival than did those given placebo.

TL;DR: Despite lower baseline risk, outcomes were similar in low- and middle-income compared with high-income countries and should also address the need for safe perioperative care.

TL;DR: It is determined that macrophage-generated CO promotes ATP production and release by bacteria, which then activates the Nacht, LRR, and PYD domains-containing protein 3 (NALP3) inflammasome, intensifying bacterial killing.

TL;DR: There is a clear need to develop a specific treatment for this progressively debilitating neurodegenerative disorder, and a review of NPC patients in the UK confirms the phenotypic variability of this inherited lipid storage disorder.

TL;DR: The epidemiological characteristics of patients at risk of ARDS are established, ventilation management in this population is described, and outcomes compared with people at no risk ofARDS are assessed.